Whether pre-ART naïve CD8+ T-cell percentages predict immune recovery and defining the role of naïve CD8+ T-cells in the individual response to other strategies that rely on host immune responses to control viral infection, such as that proposed with HIV cure [32] and therapeutic vaccination strategies are worthy of further research, particularly in determining the optimum time for ART initiation to preserve both CD4+ and CD8+ T-cell function. The gene discussed is CD8A; the disease is viral infectious disease.